GD2CART

GD2-targeted CAR-T cells

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GD2CART, covering 2025-11-03 to 2025-11-03. Get the full timeline:

Most recent: Clinical Trial Update: Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial [Phase 1]

See pricing